About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
PHENYLBUTAZONE (ID 27093) demonstrates a broad, multi‑layer biochemical activity profile affecting enzyme‑driven catalytic pathways, receptor‑regulated signalling systems, mitochondrial bioenergetics, redox‑state equilibrium, ion‑channel behaviour, cytoskeletal integrity and transcription‑factor regulatory networks. Its structural features indicate potential interactions with catalytic residues, allosteric protein domains, membrane‑bound receptors and intracellular signalling intermediates, enabling influence over phosphorylation kinetics, Ca²⁺/cAMP/IP₃/DAG‑mediated second‑messenger systems, ATP turnover, ROS buffering and mitochondrial respiratory‑chain performance.
Depending on concentration and biological conditions, PHENYLBUTAZONE may modulate metabolic flux distribution, alter mitochondrial membrane potential, influence chromatin accessibility, impact vesicular trafficking dynamics and reshape gene‑expression patterns relevant to survival, inflammation, apoptosis, autophagy, metabolic adaptation and redox‑stress response.
Benefits and Advantages
This compound is widely used across advanced biochemical, pharmacological and mechanistic research domains, including:
- Receptor–ligand interaction studies and affinity‑mapping
- Enzyme‑kinetic pathway deconstruction and catalytic‑domain profiling
- Mitochondrial‑function analysis and ATP‑flux/oxidative‑stress modelling
- Multi‑omics integration (transcriptomics, metabolomics, proteomics, phosphoproteomics)
- Cytoskeletal‑structure and membrane‑dynamics research
- Autophagy, apoptosis, necroptosis and ferroptosis signalling investigations
- SAR (structure–activity relationship) profiling and compound‑optimisation workflows
- Pharmacodynamic modelling, threshold‑activation mapping and dose–response scaling
Side Effects and Risks
Laboratory‑observed or predicted risks include:
- Oxidative imbalance and excessive ROS accumulation
- Mitochondrial overload or respiratory‑chain suppression
- Dysregulation of Na⁺/K⁺/Ca²⁺ ion‑channel homeostasis
- Unintended receptor cross‑talk or inhibitory interference
- Cytoskeletal destabilisation and membrane‑integrity disruption
- Dose‑dependent cytotoxicity with apoptosis/autophagy activation
- Transcriptional instability or epigenetic disturbance
- Inflammatory signalling activation via NF‑κB, MAPK or JNK pathways
Use strictly within controlled laboratory environments under appropriate biosafety protocols.
Datasheet
| Molecular Formula | C19H20N2O2 |
|---|---|
| Molecular Weight | 308.4 g/mol |
| CAS Number | 50-33-9 |
| Storage Condition | Stable if stored at room temperature in closed containers in absence of moisture. |
| Solubility | less than 1 mg/mL at 74.3 °F (NTP, 1992) |
| Purity | Purity information is available upon request (COA). |
| Synonym | phenylbutazone; 50-33-9; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; Butapirazol; Butazolidin |
| IUPAC/Chemical Name | 4-butyl-1,2-diphenylpyrazolidine-3,5-dione |
| InChl Key | VYMDGNCVAMGZFE-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
